7MW-4911

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug Name7MW-4911

Drug Alias Name7MW-4911

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MF6 payload

Mechanisms of ActionDNA topoisomerase I inhibitorsAnti-Cadherin-17

TargetsCadherin-17DNA topoisomerase I

Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsGastrointestinal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMabwell (Shanghai) Bioscience Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursColorectal NeoplasmsGastrointestinal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A